C12N 2740/16045
Special targeting system for viral vectors
C12N2740/16045 (Special targeting system for viral vectors) appears on 101 US grants and 200 published applications in this corpus.
Search patents in C12N- Granted patents
- 101
- Published applications
- 200
- Assignees
- 110
- Inventors
- 403
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 2 |
| 2003 | 1 | 8 |
| 2004 | 3 | 4 |
| 2005 | 1 | 9 |
| 2006 | 3 | 5 |
| 2007 | 2 | 4 |
| 2008 | 2 | 6 |
| 2009 | 3 | 3 |
| 2010 | 3 | 10 |
| 2011 | 0 | 5 |
| 2012 | 5 | 4 |
| 2013 | 4 | 5 |
| 2014 | 6 | 6 |
| 2015 | 8 | 4 |
| 2016 | 3 | 8 |
| 2017 | 3 | 4 |
| 2018 | 7 | 10 |
| 2019 | 4 | 5 |
| 2020 | 5 | 9 |
| 2021 | 2 | 4 |
| 2022 | 3 | 10 |
| 2023 | 5 | 7 |
| 2024 | 4 | 20 |
| 2025 | 10 | 28 |
| 2026 | 5 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Vectors and compositions for treating hemoglobinopathies11 Aug 2026US 12,703,864 B2Children's Medical Center Corporation
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,622 B2Massachusetts Institute of Technology
- Compositions and methods for making novel T-cell receptors21 Apr 2026US 12,606,936 B2VCreate, Inc.
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Cell surface engineered of tailored therapeutic gene delivery8 Oct 2026US 2026/0308617 A1The Children’s Hospital of Philadelphia
- Pharmaceutical compositions viral particles and methods of using the same13 Aug 2026US 2026/0234664 A1Interius Biotherapeutics, Inc.
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Dissociable envelope binding proteins and uses thereof30 Jul 2026US 2026/0217786 A1CSL Behring GmbH
- Recombinant retrovirus, compositions, and methods of use30 Jul 2026US 2026/0218136 A1Kelonia Therapeutics, Inc.
Most cited
By later US patents
- Chimeric envelope proteins for viral targeting71US 5,714,316 AThe Trustees of the University of Pennsylvania · 1998
- Modification of virus tropism and host range by viral genome shuffling34US 6,596,539 B1Maxygen, Inc. · 2003
- Methods and compositions for the activation of gamma-delta T-cells29US 10,137,144 B2American Gene Technologies International Inc. · 2018
- Fusion glycoproteins27US 5,643,756 AThe Public Health Research Institute of the City of New York, Inc. · 1997
- Lentiviral vector system for high quantity screening27US 6,830,892 B2Dana-Farber Cancer Institute, Inc. · 2004